 |
|
|
|
|
|
Introduction Human Veterinary Environmental Industrial Agricultural MSG
Introduction Medical Veterinary Environmental Industrial Agricultural
Introduction Susceptibility MIC Database Procedures Histopathology
Introduction Abbreviations Links CME Conference Highlights Bibliography Glossary Good Books Events Calendar
Introduction Our Mission Editorial Board Editorial Staff Supporters Contributors Legal Stuff Privacy Policy Kudos
Introduction Descriptions Synonyms Image Bank Lecture Bank Video Bank
This page updated:
1/27/2007 9:23:00 AM
DoctorFungus - All Rights Reserved
© 2007 Copyright
& Privacy Policy
Site built and designed for doctorfungus by Webillustrated
|
 |
 |
 |
|
You are here:
The Fungi > Descriptions >
|
Aspergillus terreus
Thom, 1918
|
Colonies on potato dextrose agar at 25°C are beige to buff to cinnamon. Reverse is yellow and yellow soluble pigments are frequently present. Moderate to rapid growth rate. Colonies become finely granular with conidial production.
Hyphae are septate and hyaline. Conidial heads are biseriate (containing metula that support phialides) and columnar (conidia form in long columns from the upper portion of the vesicle). Conidiophores are smooth-walled and hyaline, 70 to 300µm long, terminating in mostly globose vesicles. Conidia are small (2-2.5 µm), globose, and smooth. Globose, sessile, hyaline accessory conidia (2-6 µm) frequently produced on submerged hyphae.[531, 2202].
This species is noteworthy for its refractoriness to amphotericin B therapy [2202, 2203], [1440, 2367] [2152], [891]. Isolates that are initially white and producing only accessory conidia may be mistaken for Histoplasma capsulatum [2202].
| AMB |
CAS |
ITRA |
VORI |
POSA |
TERB |
5FC |
MICA |
ANID |
| 0.5 µg/ml=1 |
0.03 µg/ml=14 |
0.03 µg/ml=2 |
0.125 µg/ml=2 |
0.03 µg/ml=5 |
0.004 µg/ml=2 |
>64 µg/ml=15 |
0.03 µg/ml=6 |
0.03 µg/ml=1 |
| 1.0 µg/ml=6 |
0.06 µg/ml=16 |
0.06 µg/ml=9 |
0.25 µg/ml=22 |
0.06 µg/ml=13 |
0.015 µg/ml=2 |
|
|
|
| 2.0 µg/ml=40 |
0.125 µg/ml=37 |
0.125 µg/ml=36 |
0.5 µg/ml=60 |
0.125 µg/ml=9 |
0.03 µg/ml=5 |
|
|
|
| 4.0 µg/ml=46 |
0.25 µg/ml=20 |
0.25 µg/ml=20 |
1.0 µg/ml=11 |
|
0.06 µg/ml=1 |
|
|
|
| 8.0 µg/ml=11 |
1.0 µg/ml=1 |
0.5 µg/ml=2 |
|
|
0.125 µg/ml=1 |
|
|
|
| 16 µg/ml=1 |
2.0 µg/ml=2 |
1.0 µg/ml=3 |
|
|
|
|
|
|
| |
4.0 µg/ml=4 |
|
|
|
|
|
|
|
| Drug/N |
AMB/105 |
CAS/94 |
ITRA/72 |
VORI/95 |
POSA/27 |
| MIC Range |
0.5-8.0 |
0.03-4.0 |
0.03-1.0 |
0.25-1.0 |
0.03-0.125 |
| MIC50 |
4.0 |
0.125 |
0.125 |
0.5 |
0.06 |
| MIC90 |
4.0 |
0.25 |
0.25 |
1.0 |
0.125 |
* Fungus Testing Laboratory unpublished data (NCCLS M38-A)
PubMed
GenBank
|
|
|

References
531. de Hoog, G. S., J. Guarro, J. Gene, and M. J. Figueras. 2000. Atlas of Clinical Fungi, 2nd ed, vol. 1. Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands.
891. Graybill, J. R., S. Hernandez, R. Bocanegra, and L. K. Najvar. 2004. Antifungal therapy of murine Aspergillus terreus infection. Antimicrob. Agents Chemother. 48:3715-3719.
1440. Marr, K. A., T. Patterson, and D. Denning. 2002. Aspergillosis - Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin N Amer. 16:875-894,VI.
2152. Steinbach, W. J., D. K. Benjamin, Jr., D. P. Kontoyiannis, J. R. Perfect, I. Lutsar, K. A. Marr, M. S. Lionakis, H. A. Torres, H. Jafri, and T. J. Walsh. 2004. Infections due to Aspergillus terreus: A multicenter retrospective analysis of 83 cases. Clin Infect Dis. 39:192-198.
2202. Sutton, D. A., A. W. Fothergill, and M. G. Rinaldi (ed.). 1998. Guide to Clinically Significant Fungi, 1st ed. Williams & Wilkins, Baltimore.
2203. Sutton, D. A., S. E. Sanche, S. G. Revankar, A. W. Fothergill, and M. G. Rinaldi. 1999. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol. 37:2343-2345.
2367. Walsh, T. J., V. Petraitis, R. Petraitiene, A. Field-Ridley, D. Sutton, M. Ghannoum, T. Sein, R. Schaufele, J. Peter, J. Bacher, H. Casler, D. Armstrong, A. Espinel-Ingroff, M. G. Rinaldi, and C. A. Lyman. 2003. Experimental pulmonary aspergillosis due to Aspergillus terreus: Pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infec Dis. 188:305-319.
|
|
|
 |
 |
Home |
Image Bank |
Lecture Bank |
Knowledgebase |
Site Map |
Contact Us |
The Fungi |
Mycoses |
Drugs |
Laboratory |
Education & Tools |
About Us
|
|
|
|